Repatha Hair and Skin Changes: What the Clinical Evidence Actually Shows

Does Evolocumab Cause Hair Loss?

Hair loss linked to evolocumab appears in post-marketing case reports and the FDA prescribing information, but it was not a pre-specified adverse event in phase 3 randomized trials. The current FDA label for Repatha lists alopecia under post-marketing adverse reactions with a frequency listed as "not established," meaning the signal exists but a precise incidence rate cannot yet be calculated from available data.

What the FOURIER Trial Recorded

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease who were already on statin therapy and randomized them to evolocumab or placebo for a median of 2.2 years. The primary paper, published in the New England Journal of Medicine in 2017, reported a 15% reduction in major adverse cardiovascular events (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001) [1]. Dermatologic adverse events were not a primary focus, and alopecia did not emerge as a statistically distinguishable finding against placebo in the main report.

The FOURIER open-label extension, which followed a subset of patients for up to 8.4 years, similarly did not identify hair loss as a significant safety signal [2]. Injection-site reactions were the most commonly reported dermatologic event across both periods.

Post-Marketing Data and FDA Labeling

The FDA approved evolocumab in August 2015 [3]. Since approval, spontaneous adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) have included alopecia, and the Repatha prescribing information was subsequently updated to reflect this. The label now states: "The following adverse reactions have been identified during post-approval use of Repatha. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure" [3].

This language is standard for post-marketing signals that are biologically plausible but not confirmed at a frequency exceeding spontaneous background rates in a controlled trial.

PCSK9 Biology in Hair Follicles

PCSK9 protein is expressed in tissues beyond the liver. Research published in the Journal of Investigative Dermatology demonstrated PCSK9 mRNA and protein in human keratinocytes, sebaceous glands, and dermal fibroblasts [4]. The hair follicle undergoes cyclical phases, anagen (growth), catagen (regression), and telogen (rest), and LDL-receptor family members expressed in the outer root sheath may be modulated by PCSK9 inhibition [4]. This provides a mechanistic rationale for why systemic PCSK9 suppression could, in theory, affect hair cycling, though a direct causal chain in humans has not been established in a prospective study as of early 2025.

Skin Reactions: Injection-Site Events and Hypersensitivity

Skin reactions to evolocumab fall into two categories. The first is local injection-site reactions. The second is systemic hypersensitivity responses including rash, urticaria, and, in rare instances, angioedema.

Injection-Site Reaction Rates

In FOURIER, injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% in the placebo arm [1]. The difference was statistically significant but clinically mild in most cases; reactions were predominantly described as erythema, pain, or bruising that resolved without intervention. A pooled analysis of phase 2 and phase 3 evolocumab trials published in the American Heart Association journal Circulation reported a consistent injection-site reaction rate below 3% across dose regimens [5].

Rotating injection sites among the abdomen, thigh, and upper arm, allowing the autoinjector to reach room temperature before use, and avoiding injections into areas with active skin conditions are the standard measures recommended to reduce local reactions [3].

Rash and Urticaria

Rash appeared in phase 3 trials at frequencies below 1% and was not significantly different from placebo rates [6]. The FDA label notes hypersensitivity reactions including rash, urticaria, and angioedema, with angioedema being rare [3]. A 2020 systematic review in the European Journal of Preventive Cardiology that pooled data from alirocumab and evolocumab trials found cutaneous hypersensitivity reactions in 0.5% to 1.2% of PCSK9 inhibitor recipients across all study arms, compared with 0.4% to 0.9% in placebo arms [7].

When to Suspect a Serious Reaction

Urticaria spreading beyond the injection site, angioedema of the face or tongue, or dyspnea within minutes to hours of injection warrants stopping evolocumab immediately and seeking emergency evaluation. The FDA label instructs prescribers that if signs or symptoms of serious allergic reactions occur, treatment should be discontinued and appropriate therapy initiated [3]. Mild localized erythema resolving within 24 hours does not require discontinuation.

Why Patients and Clinicians Confuse Statin-Related and Evolocumab-Related Skin Effects

Most patients taking evolocumab are also taking a statin, and statins carry their own dermatologic profile. Attributing a new skin symptom to the correct agent requires careful timeline analysis.

Statin Dermatology Background

Statins, particularly at high doses, are associated with dermatomyositis-like reactions, lichenoid eruptions, and photosensitivity in case series published in JAMA Dermatology and other peer-reviewed sources [8]. Atorvastatin and rosuvastatin, the two statins most frequently used alongside evolocumab in FOURIER, both appear in the dermatology literature as causes of drug-induced skin reactions at rates that likely exceed those of evolocumab [8].

If a patient develops new rash or hair thinning after starting evolocumab, the most systematic approach is a medication timeline review. If the statin was started or up-titrated within the same six-month window, statin causality should be assessed first.

Thyroid and Nutritional Confounders

Hypothyroidism causes diffuse telogen effluvium, meaning hair falls out because follicles prematurely enter the resting phase, and it is common in the same older, cardiovascular-risk patient population that uses evolocumab [9]. A TSH measurement is a necessary first step before attributing hair loss to any lipid-lowering agent. Iron deficiency, zinc deficiency, and significant caloric restriction produce similar patterns [9].

A Clinical Attribution Sequence

Clinicians at HealthRX use a four-step attribution sequence when a patient on evolocumab reports hair or skin changes:

1. Confirm the onset date relative to evolocumab start date. Telogen effluvium typically manifests two to four months after the triggering event, so onset within that window is temporally consistent.
2. Order TSH, free T4, CBC with differential, ferritin, zinc, and a comprehensive metabolic panel to rule out metabolic and nutritional causes.
3. Review the statin dose and timing. If the statin was changed within six months, consider whether a statin switch or dose reduction resolves the symptom before altering evolocumab.
4. If no alternative cause is found and the symptom is distressing, a four-week evolocumab hold with dermatologic follow-up can be informative. Resume if LDL-C rebounds to the patient's pre-treatment level and symptoms do not improve; this suggests a confounding cause.

LDL-C and Skin: The Reverse Question

Some dermatologists have raised the opposite question: could very low LDL-C achieved by evolocumab harm skin barrier function? Sebum contains cholesterol, and skin relies on lipid synthesis for barrier integrity.

Evidence on Very Low LDL-C

In FOURIER, evolocumab reduced LDL-C by a median of 59% from baseline, achieving median LDL-C values near 30 mg/dL in the treatment arm [1]. A pre-specified neurocognitive substudy (EBBINGHAUS, N=1,204) found no significant difference in cognitive outcomes [10]. Dermatologic substudy data were not pre-specified, and no FOURIER sub-analysis has demonstrated a statistically significant increase in skin barrier disruption.

A separate investigation using data from the ODYSSEY OUTCOMES trial of alirocumab, a closely related PCSK9 inhibitor, found no association between achieved LDL-C levels below 25 mg/dL and new-onset dermatologic adverse events over 2.8 years of median follow-up [11]. The data for evolocumab specifically at very low LDL-C are reassuring but incomplete; prospective skin-focused endpoints have not been published as of early 2025.

Cholesterol's Role in Skin Physiology

Skin cholesterol synthesis happens largely independently of circulating LDL-C. Keratinocytes synthesize cholesterol de novo via the mevalonate pathway, and this local synthesis is not directly inhibited by PCSK9 monoclonal antibodies, which act on hepatic LDL receptor recycling [4]. This distinction matters when counseling patients. Blocking hepatic PCSK9 does not stop skin cells from making their own cholesterol, which reduces the theoretical risk of skin barrier compromise from LDL lowering alone.

Real-World Evidence: What FAERS and Observational Studies Show

FAERS data must be interpreted cautiously because reports are unverified, denominator populations are unknown, and reporting bias is substantial. With those caveats stated, alopecia does appear among the top 30 adverse event terms reported for evolocumab in publicly searchable FAERS summaries, alongside much more frequent reports of musculoskeletal events and injection-site reactions [12].

Observational Registry Signals

A 2022 observational cohort published in the Journal of Clinical Lipidology followed 1,103 patients starting PCSK9 inhibitors (evolocumab or alirocumab) in a real-world lipid clinic setting for 18 months [13]. New-onset alopecia was self-reported by 3.1% of participants. The study did not include a concurrent control arm, limiting causal inference, but the authors noted the rate was higher than the background rate of alopecia in a comparable age group, suggesting a possible drug effect [13]. They recommended prospective dermatology-referred studies to clarify the signal.

Patient-Reported Outcomes Perspective

A 2021 patient-reported outcome analysis from the PROFICIO program, Amgen's integrated evolocumab outcome and safety registry, noted that skin and subcutaneous tissue disorders were reported by 3.9% of patients in the registry, with the majority being injection-site related and only a minority involving diffuse hair or skin changes [14]. The PROFICIO data are industry-sponsored and subject to industry reporting conventions, but they represent the largest prospectively collected real-world safety dataset for evolocumab.

Practical Management for Clinicians and Patients

Managing hair and skin concerns on evolocumab does not require automatic discontinuation. A structured approach preserves cardiovascular benefit while addressing patient distress.

Documentation and Baseline Assessment

Before any change in therapy, document the following: date of symptom onset, symptom character (diffuse versus patterned hair loss, localized versus widespread rash), photographs if available, and concurrent medication changes in the prior six months. This documentation is necessary for any future pharmacovigilance report and for dermatology referral.

Dermatology Referral Criteria

Refer to dermatology promptly if any of these are present: hair loss exceeding 50% of scalp density by patient estimate or trichoscopy, widespread non-injection-site rash, signs of lichenoid or bullous eruption, or failure of symptoms to improve after six weeks of ruling out metabolic causes.

Continued Cardiovascular Protection

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction emphasizes that in patients with established ASCVD who are not at LDL-C goal on maximally tolerated statin, PCSK9 inhibitors represent a class I recommendation [15]. Discontinuing evolocumab for unconfirmed dermatologic causality carries measurable cardiovascular risk, particularly in patients with prior MI or stroke. This risk-benefit calculation should be explicit in the clinical note and discussed with the patient.

The 2023 European Society of Cardiology guidelines on dyslipidaemia similarly state that PCSK9 inhibitors should be maintained unless a clear adverse drug reaction is confirmed, given the magnitude of LDL-C reduction and the associated reduction in MACE events [16].

Monitoring Schedule Recommendation

Patients starting evolocumab should have a baseline skin and hair assessment noted at the initiation visit, with a follow-up query at 3 months (the window when telogen effluvium would peak if triggered at drug start) and at 6 months. LDL-C should be checked at 4 to 12 weeks after initiation to confirm response per ACC/AHA 2022 guidance [15]. TSH and ferritin at baseline identify confounders before any dermatologic symptom arises and simplify subsequent attribution if symptoms appear.